Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiedu Pingchan is a Traditional Chinese Medicine (TCM) formula developed by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine for the treatment of Parkinson's disease. Formulated as an oral granule, it is designed based on the TCM theory of 'clearing heat and detoxifying' to address the 'toxin-heat' pathogenesis associated with the progression of Parkinson's. The formula typically comprises several herbal components, including Arisaema cum Bile and Scutellaria baicalensis, which work synergistically to provide neuroprotective effects. Research suggests that Jiedu Pingchan exerts its therapeutic benefits by inhibiting the aggregation of alpha-synuclein, suppressing neuroinflammation through the modulation of the NLRP3 inflammasome pathway, and preventing the loss of dopaminergic neurons in the substantia nigra. It is primarily utilized as an adjunctive therapy to standard levodopa treatment to improve motor symptoms and reduce long-term complications such as dyskinesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiedu Pingchan.